The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 193.00
Bid: 190.00
Ask: 196.00
Change: -42.00 (-17.65%)
Spread: 6.00 (3.158%)
Open: 238.00
High: 196.00
Low: 196.00
Prev. Close: 238.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Beowulf raises funds for Kallak iron ore project

Mon, 04th Mar 2024 19:59

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Beowulf Mining PLC - London-based mining company with projects in Sweden, Finland and Kosovo - Announces terms of previously announced fundraise. Says rights issue of Swedish depository receipts will raise up to GBP6.3 million, while a retail offer of ordinary shares in the UK will raise around GBP1.6 million. Notes the SDRs will be offered at SEK0.08 each and the shares at 0.61 pence each. Adds the SDRs will also be offered for subscription, without preferential rights, to institutional investors, other professional investors and the general public in Sweden. Beowulf says it has has received underwriting commitments for the rights issue for around 60% of the total. Explains proceeds will be used mainly to finance the continued development of the Kallak iron ore project in northern Sweden, including completion of the ongoing pre-feasibility study and environmental studies. Funds will also repay amounts advanced under the bridge loan financing arrangements, and corporate costs.

----------

Kefi Gold & Copper PLC - exploration and development company focused on gold and copper projects in the Arabian-Nubian Shield - Plans to raise GBP4.5 million placing at 0.6 pence per share. Further, issues 83.3 million shares to cover accrued fees to certain directors and advisers. In addition, launches retail offer at the same issue price. Explains funds will underpin the launch of the Tulu Kapi Gold project by mid-2024.

----------

LungLife AI Inc - California-based developer of clinical diagnostic solutions for early lung cancer detection - Plans to raise around GBP1.8 million via a GBP1.56 million placing at 35 pence each and a GBP250,000 subscription at the same price. Explains net proceeds, along with existing cash resources, are expected to be utilised to establish the commercial proof of concept of the company's LungLB test. Notes funding is expected to provide the company with a cash runway to early April 2025.

----------

RC365 Holding PLC - London-based company focusing on payment gateway solutions and IT support services - Enters into an unsecured convertible loan note with Mill End Capital Ltd for up to GBP4 million. Says net proceeds of the unsecured loan will be used for the continuing development of existing operations with a particular focus on expanding operations in Malaysia, Japan and the UK. States the first tranche of the CLN comprises GBP600,000, the second tranche a further GBP1.4 million. Any further tranche shall be at the written request of RC365 and discretion of the lender, but will not exceed GBP4 million, RC365 says.

----------

Faron Pharmaceuticals Ltd - Turku-Finland-based clinical-stage biopharmaceutical company - Announces binding commitments worth GBP3.2 million for convertible loans obtained from certain existing shareholders. Explains this allows it to make critical payments to third parties under agreed waivers with IPF. Says this secures its short-term financing needs until the end of March. Faron says talks continue to secure its short and longer-term financing needs, including first additional bridge financing of around EUR5 million. In addition to the short-term bridge financing, Faron intends to propose to the Annual General Meeting an authorization for a larger share issue. In total, Faron expects to need EUR35 million of financing to complete the enrolment of the phase 2 of the BEXMAB study and to obtain regulatory feedback from the US Food & Drug Administration. At February 19, notes cash and cash equivalents held by Faron totalled EUR4.3 million.

----------

Supernova Digital Assets PLC - looks to identify investment and business building opportunities in the Solana and crypto currency ecosystem - Plans return to shareholders. Intends to achieve this by purchasing its own shares through a tender offer. Further, raises GBP242,000 via placing at 0.1 pence per share.

----------

Celsius Resources Ltd - explorer focused on portfolio of copper-gold resources in the Philippines - Advises that trading will be halted on the Australian Securities Exchange effective from March 5 further to the company's request. Celsius says it requested the suspension ahead of an announcement in relation to its flagship Maalinao-Caigutan-Biyog copper-gold project and the issuance of project sensitive documents by the Philippine National Government. Says trading on the AIM market of the London Stock Exchange remains unaffected.

----------

Kibo Energy PLC - Galway, Ireland-based company with energy projects in Africa and the UK - Sells shares in its subsidiary Mast Energy Developments PLC worth GBP29,350. Notes proceeds will be used to pay down the balance balance on the bridge loan facility with RiverFort Global Opportunities PCC Ltd. Holds 33% stake in MED following the share sale.

----------

Braveheart Investment Group PLC - Dodworth, England-based investment company - Provides update on one of its investments, Paraytec Ltd. Notes Paraytec develops high performance specialist detectors for the analytical and life sciences instrumentation markets. In December, Braveheart sought a buyer for Paraytec, of which it owns 100%. But, notes it has been unable to secure an attractive offer and therefore decides to retain Paraytec within its portfolio.

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
21 Feb 2019 10:09

Faron Pharmaceuticals shares surge on latest Clevegen data

(Sharecast News) - Shares in Faron Pharmaceuticals were surging on Thursday morning, after it announced an update on early observations on immunity and clinical response of MATINS patients after administration of its 'Clevegen' product.

Read more
13 Feb 2019 12:20

Faron Pharmaceuticals Encouraged By Clever-1 Antibody Study Result

LONDON (Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said new data supports the use of Clever-1 antibodies in re-activating an immune response to tumours.Shares in Faron were up

Read more
19 Dec 2018 11:07

Faron Pharmaceuticals pins some hope to YODA trial

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals issued interim results from its pharmacokinetic/dynamic 'YODA' study on Wednesday, examining various formulations of recombinant human interferon-beta (IFN-beta).

Read more
14 Dec 2018 15:57

Dosing begins in Faron's study of 'Clevegen' drug

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Friday that the first patient has successfully been dosed in the phase I/II MATINS study of Clevegen, its wholly-owned novel precision cancer immunotherapy drug.

Read more
5 Dec 2018 11:19

WINNERS & LOSERS SUMMARY: Ashtead Falls On US Economic Slowdown Worry

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Wednesday.----------FTSE 100 - up 2.7%. Japan's Takeda Pharmaceutical

Read more
5 Dec 2018 10:13

Traumakine treatment optimal for particular subgroup, Faron finds

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals has identified, by genetic testing, an "optimal subgroup" of acute respiratory distress syndrome (ARDS) patients for Traumakine treatment who showed a substantial reduction in mortality during the INTEREST trial, it announced on Wednesday.

Read more
5 Dec 2018 09:09

Faron Pharmaceuticals Finds "Optimal" Patient Group For Traumakine

LONDON (Alliance News) - Faron Pharmaceuticals Ltd shares jumped on Wednesday as the company said it identified an "optimal" subgroup of patients, with a certain genetic mutation, to be

Read more
3 Dec 2018 10:50

WINNERS & LOSERS SUMMARY: McColl's Retail Plunges After Profit Warning

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Monday.----------FTSE 100 - up 8.9%, Evraz, up 7.8%, up

Read more
3 Dec 2018 10:09

Faron Pharmaceuticals applies to begin Clevegen clinical trials

(Sharecast News) - Clinical stage biopharmaceutical company Faron Pharmaceuticals announced on Monday that its clinical trial application to conduct a Phase I/II study with 'Clevegen', its wholly-owned novel precision cancer immunotherapy drug in development for the treatment of selected metastatic or inoperable tumours, has been approved by the Finnish Medicines Agency (FIMEA).

Read more
6 Nov 2018 16:29

DIRECTOR DEALINGS: Faron Divisional Chief Medical Officer Buys Shares

LONDON (Alliance News) - Faron Pharmaceuticals Oy on Tuesday said VP Drug Development Chief Medical Officer Matti Karvonen acquired shares in the biopharmaceutical company.In a transaction

Read more
22 Oct 2018 15:32

Faron Reports Corticosteroids Interference In Traumakine Trial

LONDON (Alliance News) - Faron Pharmaceuticals Ltd said Monday that it has found evidence suggesting that corticosteroids used in parallel to its Traumakine treatment had a significant effect on a

Read more
17 Sep 2018 10:37

Faron Pharmaceuticals Submits Clinical Trial Application For Clevegen

LONDON (Alliance News) - Faron Pharmaceuticals Oy said Monday it has filed a clinical trial application for its cancer immunotherapy drug Clevegen.Clevegen, an anti-Clever-1 antibody, the a

Read more
13 Sep 2018 10:49

WINNERS & LOSERS SUMMARY: Retailers Hit As John Lewis Profit Collapses

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - WINNERS----------Royal Bank a

Read more
13 Sep 2018 10:30

Faron Pharmaceuticals Falls As Interim Loss Widens On Research Costs

LONDON (Alliance News) - Shares in Faron Pharmaceuticals Ltd dropped on Thursday after the company said its loss for the first half of its financial year increased on higher research were trading

Read more
13 Sep 2018 08:36

Faron losses widen following disappointing Traumakine trial

(Sharecast News) - Faron Pharmaceuticals' operating loss doubled in the first half of its trading year following the group's disappointing trial on its Traumakine treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.